Long-term safety profile of siplizumab, a humanized anti-CD2 monoclonal antibody, in subjects with chronic plaque psoriasis

Barbara White, Brian Harris

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Prolonged depletion of activated T cells via targeted therapy may reduce disease activity in chronic plaque psoriasis, but may potentially lead to increased risk of serious infection.Objectives: To evaluate the long-term safety profile of siplizumab, an anti-CD2 monoclonal antibody, in chronic plaque psoriasis subjects who experienced persistent siplizumab-induced lymphocyte depletion.Methods: Subjects (n=94) with absolute lymphocyte counts (ALC) >30% lower than baseline or absolute CD4 count

Original languageEnglish (US)
JournalInternet Journal of Dermatology
Volume7
Issue number2
StatePublished - 2009
Externally publishedYes

Keywords

  • Clinical trial
  • Long-term
  • Lymphocyte depletion
  • Psoriasis
  • Safety

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Long-term safety profile of siplizumab, a humanized anti-CD2 monoclonal antibody, in subjects with chronic plaque psoriasis'. Together they form a unique fingerprint.

Cite this